IGHE and cancer: The propensity of basophils from cancer patients to be activated by non-IgE signals and by IgE antibodies both in the clinical testing of IgE immunotherapies and in the pre-clinical development of novel IgE antibodies has not been extensively undertaken in larger patient cohorts.